ProfileGDS5678 / 1453629_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 22% 21% 21% 22% 22% 22% 21% 22% 22% 22% 22% 22% 21% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.544522
GSM967853U87-EV human glioblastoma xenograft - Control 22.5034521
GSM967854U87-EV human glioblastoma xenograft - Control 32.5065521
GSM967855U87-EV human glioblastoma xenograft - Control 42.4744422
GSM967856U87-EV human glioblastoma xenograft - Control 52.460522
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5749222
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5387721
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.493822
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4831122
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5041422
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5029322
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4870922
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4955421
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.512522